BTAIQ BioXcel Therapeutics, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1720893 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-14.5%
TTM net income YoY-39.1%
TTM EPS YoY78.3%
Revenue 3-yr CAGR-10.6%
Net income 3-yr CAGR—
Margins
Gross margin53.1%
Operating margin-6,054.7%
Net margin-9,549.9%
FCF margin-6,860.4%
EBITDA margin-6,024.4%
Returns
ROE—
ROA-259.6%
ROIC (approx.)—
Asset turnover0.03x
Leverage & solvency
Liabilities / assets500.9%
Debt / equity—
Current ratio0.21x
Interest coverage-2.61x
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-73.1%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $182,000 | $206,000 | $256,000 | $98,000 | $120,000 | $168,000 | $366,000 | $214,000 |
| Cost of revenue | $22,000 | $283,000 | $32,000 | $11,000 | $107,000 | $14,000 | $832,000 | $1.17M |
| Gross profit | $160,000 | -$77,000 | $224,000 | $87,000 | $13,000 | $154,000 | -$466,000 | -$956,000 |
| R&D expense | $3.16M | $2.96M | $6.70M | $8.74M | $10.26M | $4.55M | $5.90M | $5.10M |
| SG&A expense | $7.19M | $7.19M | $3.81M | $5.38M | $5.61M | $5.70M | $4.09M | $7.68M |
| Operating income | -$10.19M | -$10.22M | -$10.28M | -$14.23M | -$15.85M | -$10.10M | -$10.49M | -$15.29M |
| Interest expense | $4.26M | $4.20M | $4.40M | $4.37M | $4.22M | $3.99M | $4.03M | $3.79M |
| Net income | -$14.71M | -$12.69M | -$12.54M | -$30.91M | -$19.19M | -$7.25M | -$10.86M | -$13.65M |
| EBITDA | -$10.18M | -$10.16M | -$10.21M | -$14.15M | -$15.78M | -$10.02M | -$10.42M | -$15.22M |
| EPS (basic) | -0.49 | -0.54 | — | -2.18 | -2.45 | -1.50 | — | -5.15 |
| EPS (diluted) | -0.49 | -0.54 | — | -2.18 | -2.45 | -1.50 | — | -5.15 |
| Weighted avg. shares (diluted) | 30.30M | 23.57M | — | 14.20M | 7.84M | 4.83M | — | 2.65M |
| Balance sheet | ||||||||
| Cash & equivalents | $12.84M | $17.18M | $28.41M | $36.18M | $17.43M | $31.01M | $29.85M | $40.39M |
| Receivables | $82,000 | $216,000 | $233,000 | $0 | $17,000 | — | $131,000 | $3,000 |
| Inventory | $483,000 | $500,000 | $722,000 | $459,000 | $506,000 | $642,000 | $679,000 | $1.52M |
| Current assets | $28.70M | $33.91M | $44.69M | $44.40M | $25.24M | $37.78M | $37.39M | $47.79M |
| PP&E, net | $99,000 | $117,000 | $175,000 | $249,000 | $324,000 | $399,000 | $475,000 | $552,000 |
| Total assets | $28.80M | $34.02M | $44.92M | $44.79M | $25.79M | $38.57M | $38.34M | $48.89M |
| Current liabilities | $137.15M | $54.99M | $53.93M | $37.80M | $33.38M | $25.55M | $22.23M | $25.56M |
| Short-term debt | $104.45M | $22.43M | $24.93M | $16.82M | $11.22M | $5.61M | $0 | — |
| Long-term debt | $0 | $77.86M | $84.66M | $92.30M | $97.47M | $99.92M | $102.51M | $104.44M |
| Total debt | $104.45M | $100.29M | $109.59M | $109.12M | $108.69M | $105.53M | $102.51M | $104.44M |
| Total liabilities | $144.26M | $139.57M | $140.38M | $133.71M | $133.46M | $128.74M | $131.44M | $134.53M |
| Shareholders' equity | -$115.46M | -$105.54M | -$95.46M | -$88.92M | -$107.67M | -$90.17M | -$93.10M | -$85.63M |
| Net debt | $91.61M | $83.11M | $81.18M | $72.95M | $91.25M | $74.51M | $72.65M | $64.05M |
| Shares outstanding | 31.30M | 27.07M | 22.33M | 20.00M | 6.62M | 5.47M | 3.10M | 42.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.10M | -$11.81M | -$14.21M | -$18.79M | -$12.57M | -$12.04M | -$14.81M | -$16.34M |
| Capital expenditure | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | -$6.10M | -$11.81M | -$14.21M | -$18.79M | -$12.57M | -$12.04M | -$14.81M | -$16.34M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $2.72M | $232,000 | $5.65M | $37.53M | $137,000 | $13.20M | $4.28M | $454,000 |
| Depreciation & amortization | $18,000 | $58,000 | $74,000 | $75,000 | $75,000 | $76,000 | $77,000 | $77,000 |
| Stock-based compensation | $358,000 | $435,000 | $450,000 | $581,000 | $1.56M | $180,000 | -$199,000 | $1.86M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.